NCT06773624 Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
| NCT ID | NCT06773624 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Small Bowel Neoplasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2021-04-23 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 18 participants in total. It began in 2021-04-23 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The neuroendocrine neoplasms of the small intestine (Si-NENs) is a relatively rare malignancy. Surgical resection is the only curative treatment for the early-stage. It remains controversial its application for advanced metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The identification of metastatic disease and tumor grade are the most important prognostic factors in advanced GEPNETs. Therefore, precise staging and evaluation of disease burden with a reliable imaging method is crucial for determining the correct stage of the disease and consequently the correct treatment. A unique feature of NeuroEndocrinal Tumors (NETs) is the expression of somatostatin receptors (SSTR) which can be targeted with radiolabeled peptides for imaging. The Positron Emission Tomography-Computed Tomography (PET/CT) technique using somatostatin analogs labeled with the positron emitting isotope, 68Ga (68Ga-DOTA peptides), has been shown to offer advantages over conventional imaging modalities as well as additional important quantitative and qualitative diagnostic information. The aim of this study is to calculate the sensitivity (SE), the specificity (SP), the positive and negative predictive values (PPV and NPV) and the overall accuracy of 68Ga-DOTATOC PET/CT-enterography in detecting in primary lesion and multifocality of siNETs.
Eligibility Criteria
Inclusion Criteria: * patients with small bowel neuroendocrine tumours * tumors with any grade (from 1 to 3) and any Ki 67 percentage * patients eligible for surgical resection Exclusion Criteria: * patients with synchronous other oncological disease * patients with Inflammatory bowel disease * patients Not eligible for surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06773624 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Small Bowel Neoplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06773624 currently recruiting?
Yes, NCT06773624 is actively recruiting participants. Contact the research team at luigi.funicelli@ieo.it for enrollment information.
Where is the NCT06773624 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06773624 clinical trial?
NCT06773624 is sponsored by European Institute of Oncology. The trial plans to enroll 18 participants.